Aim: The aim of this study was to assess the factors which influence the care pathway after discharge from an acute palliative supportive care unit (APSCU). Methods: Patients' demographics, indications for admission, kind of admission, the presence of a caregiver, awareness of prognosis, data on anticancer treatments in the last 30 days, ongoing treatment (on/off or uncertain), the previous care setting, analgesic consumption, and duration of admission were recorded. The Edmonton Symptom Assessment Scale (ESAS) at admission and at time of discharge (or the day before death), CAGE (cut down, annoy, guilt, eye-opener), and the Memorial Delirium Assessment Scale (MDAS), were used. At time of discharge, the subsequent referral to other care settings (death, home, home care, hospice, oncology), and the pathway of oncologic treatment were reconsidered (on/off, uncertain). Results: A total of 314 consecutive cancer patients admitted to the APSCU were surveyed. Factors independently associated with on-therapy were the lack of a caregiver, home discharge, and short hospital admission, in comparison with off-treatment, and less admission for other symptoms, shorter hospital admission, discharge at home, and better well-being, when compared with "uncertain." Similarly, many factors were associated with discharge setting, but the only factor independently associated with discharge home was being "on-therapy." Conclusions: The finding of this study is consistent with an appropriate selection of patients after being discharged by an APSCU, that works as a bridge between active treatments and supportive/palliative care, according the concept of early and simultaneous care.
|Number of pages||5|
|Journal||AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS|
|Publication status||Published - 2018|
All Science Journal Classification (ASJC) codes
- Cancer Research
Casuccio, A., Adile, C., Mercadante, S., & Ferrera, P. (2018). Factors Influencing Clinical and Setting Pathways after Discharge from an Acute Palliative/Supportive Care Unit. AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS, 42, 265-269.